Cryopreservation of Human Spermatozoa Cryopreservation of Human Spermatozoa


ABSTRACT Cryopreservation of human spermatozoa is a preventive therapeutic option for patients diagnosed with testicular cancer, Hodgkin's disease, lymphomas and/or other kinds of malignant diseases. Patients who are in the reproductive age group and have not yet established their families may become sterile following chemotherapy, radiation or surgical treatments. Cryopreservation of semen can ensure future fertility for these men. Extensive studies conducted in the Andrology Research Laboratory have demonstrated the ability of the spermatozoa obtained from patients with cancer to survive the damaging effects of freezing and thawing. We found that the poor quality of sperm before freezing in some men with malignancy could explain the poor post-thaw sperm survival. Prefreeze or post-thaw quality of semen is not affected by the type of disease, and post-thaw motility could be predicted with prefreeze sperm motility. We have found that successful pregnancy can be achieved when prefreeze semen quality is poor in patients with cancer, even when stored for long periods. Intracytoplasmic sperm injection (ICSI) is a good option in these patients if other assisted reproductive techniques fail. Semen cryopreservation should, therefore, be strongly recommended for all patients with cancer, even when prefreeze semen quality is very poor. In other studies, we have examined the significance of cryopreserving sperm aspirates at the time of excurrent ductal reconstruction for failure of procedure or subsequent obstruction after initial success and patency. We studied sperm aspirates in men undergoing reconstruction of the excurrent duct, and sperm aspiration or microsurgical epididymal sperm aspiration, and examined these specimens for an association of the sperm with the cause and site of obstruction. We found a lack of association between the cause and site of obstruction with cryosurvival of aspirated epididymal or vasal sperm.

Download full-text


Available from: Ashok Agarwal, Jan 23, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We determined whether cryopreserved sperm samples obtained from cancer patients before treatment respond to artificial motility stimulants and if this response is related to the extent of disease. Pre-freeze distribution of disease stage in the different types of cancer and the percentage of the population with or without oligospermia before cryopreservation were examined. Cryopreserved semen samples from 17 cancer patients (10 with testicular cancer, 5 with Hodgkin's disease and 2 with other metastatic disease) were examined for a relationship between post-thaw sperm motion characteristics and patient age or status (survived versus died) and type of disease. Motion characteristics (curvilinear velocity, straight line velocity, average path velocity, linearity and amplitude of lateral head displacement) were analyzed on a computer assisted semen analyzer before (time 0), and 30 and 60 minutes after addition of a 2.5 mM. concentration of pentoxifylline and 2-deoxyadenosine. Post-thaw sperm motion characteristics were not correlated with patient age or status, whether they did or did not have oligospermia, or type of cancer. Compared to baseline values, sperm motion characteristics increased significantly after stimulation at time 0 (p < 0.02) and at 60 minutes (p < 0.05). Oligospermic or nonoligospermic specimens responded to the same extent with pentoxifylline and 2-deoxyadenosine. A negative correlation was noted between overall stage, and type of disease and motion characteristics. Sperm banking should be encouraged at cancer diagnosis regardless of semen quality. Artificial stimulation of sperm motility results in significant improvement in sperm motion characteristics.
    The Journal of Urology 03/1997; 157(2):521-4. DOI:10.1097/00005392-199702000-00030 · 3.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether type of cancer and response to treatment was related to prefreeze or post-thaw semen quality and to predict post-thaw sperm motility from prefreeze motility. Retrospective study. Tertiary care institution. One hundred six cancer patients cryopreserving their semen specimens. Computer-assisted semen analysis was performed before and after cryopreservation on each patient specimen. The relationship of sperm motility and motion characteristics to type of cancer and patient's response to treatment. Prefreeze and post-thaw semen quality did not differ between patients presenting with testicular cancer and Hodgkin's disease. Patients with leukemia or advanced soft tissue cancer had a higher prefreeze and post-thaw motility and higher total and motile sperm count than testicular and Hodgkin's disease patients. A prefreeze sperm motility of > or = 15% could predict a post-thaw motility of > 10%. Prefreeze or post-thaw semen quality in cancer patients is not affected (except the prefreeze motile sperm count within the testicular cancer patients) by the type of disease. Prefreeze motility can predict post-thaw motility. Cryopreservation of semen should be offered to cancer patients irrespective of the type of disease.
    Fertility and Sterility 03/1997; 67(2):326-31. DOI:10.1016/S0015-0282(97)81919-X · 4.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cryopreservation of semen from patients with malignant diseases (primarily testicular cancer, Hodgkin's disease and lymphoma) before specific chemotherapy, radiation or surgical therapy has become a realistic option to preserve fertility. Nevertheless, the post-thaw sperm quality in these patients is poor. Whether the clinical diagnosis of malignancy affects the cryopreservation of human sperm is unknown. Such an association could allow post-thaw sperm quality to be predicted. We compared the effect of cryopreservation on sperm motility, velocity, linearity, amplitude of lateral head movement, motility index and motile sperm count in specimens from 30 normal men, 34 with testicular cancer, 39 with Hodgkin's disease, and 19 with leukemia and lymphoma who were referred for sperm banking during a 5-year period. The pre-freeze and post-thaw motility, motility index and motile sperm count were significantly lower in patients than in normal men (p < 0.01). No significant differences were noted among the patient groups. Similarly, no significant differences were noted after cryopreservation. Our results indicate that the poor pre-freeze sperm quality in some patients with malignancies explains the poor post-thaw results. However, the deterioration in sperm function after cryopreservation of semen among patients with different malignancies and normal donors appears to be similar. Clinical diagnosis of malignancy is not an adequate predictor of the effect of cryopreservation on human semen.
    The Journal of Urology 03/1996; 155(3):934-8. DOI:10.1016/S0022-5347(01)66350-X · 3.75 Impact Factor